The efficacy and safety of SGLT-2 inhibitors as a single or combination therapy for treatment of type 2 diabetes (T2DM) has been demonstrated in a number of studies13, 14, 15, 16. Here, SLC5A2 is linked to type 2 diabetes mellitus.